What does it take to demonstrate CAR T-cell product quality? Explore the analytical strategies shaping clinical and commercial manufacturing.

AdobeStock_2047493928

How can manufacturers demonstrate CAR T-cell product quality through reliable and reproducible analytical testing?

As CAR T-cell therapies progress through clinical development and towards commercial manufacturing, robust analytical methods are essential for characterising products, assessing quality and supporting consistent manufacturing.

Developing reliable analytical strategies for complex CAR T-cell products presents several challenges, particularly when methods need to deliver reproducible results and meet the requirements of clinical-stage manufacturing.

This webinar will explore the analytical approaches needed to support CAR T-cell manufacturing, from in-process monitoring and product characterisation through to quality control (QC) and lot-release testing.

Industry experts will discuss methods for assessing CAR expression and cell phenotype, selecting appropriate analytical assays and implementing consistent, GMP-compatible testing strategies.

The discussion will also examine assay validation, reagent qualification and evolving regulatory expectations, including the considerations involved in transferring analytical methods from process development into clinical manufacturing.

What you will learn:

  • Analytical approaches for characterising CAR T-cell products, including CAR expression, cell identity, purity and phenotype.
  • Selecting appropriate analytical methods for different stages of CAR T-cell manufacturing and product assessment.
  • Considerations for developing robust and reproducible analytical assays for QC and lot-release testing.
  • The role of cell selection and enrichment in manufacturing and analytical workflows.
  • Challenges associated with assay validation, reagent qualification and analytical method consistency.
  • Considerations for transferring analytical methods from process development into GMP-compatible clinical manufacturing.

 Register for the webinar

Who should attend? 

This webinar is relevant to professionals involved in CAR T-cell development, analytical testing and manufacturing, including:

  • Pre-clinical and drug development professionals

  • CAR T-cell process development teams

  • Clinical manufacturing and technical operations professionals

  • Analytical development and quality control specialists

  • Pharmaceutical and biotechnology organisations

  • Cell therapy CDMOs

  • Academic institutions and hospital-based cell therapy teams

Explore the analytical challenges involved in demonstrating CAR T-cell product quality and the testing strategies supporting consistent clinical manufacturing.

Register today to reserve your place.

Is the panel discussion free?

Yes – there is no charge to watch the panel discussion, either live or on-demand.

When will the panel discussion take place?

The webinar will be taking place on 27 January 2027 at 3pm (GMT).

Can I watch it later?

The panel discussion will become available to watch on-demand shortly after the live webinar takes place.

What are the benefits of attending live?

You’ll be able to ask the speakers your questions, which will be answered live in the Q&A towards the end of the session.

How long will the panel discussion be?

This panel discussion will last up to an hour.

What do I need to watch this panel discussion?

All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.

Speakers to be announced.

Register now to secure your place

2027-01-27T15:00:00
2027-01-27T15:00:002027-01-27T16:00:00
Online